Form 4 for LNTH Lantheus Holdings, Inc.
Accepted 2023-03-06 00:00:00 ET · period of report 2023-03-02 · accession 0000899243-23-007265 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-03-06 | 2023-03-02 | LNTH | Provost Jean-Claude | Chief Medical Off | A - Grant | $0.00 | +16.4K | 20.8K | +366% | $0 |
| DI | 2023-03-06 | 2023-03-02 | LNTH | Provost Jean-Claude | Chief Medical Off | A - Grant | $0.00 | +9,535 | 9,535 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | A | A | 16,359 | $0.00 | 20,823 | I By Theranostics Consulting SAS | — | — | (F2) The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| 2 | Derivative | Stock Option (right to buy) | 2023-03-02 | A | A | 9,535 | $0.00 | 9,535 | I By Theranostics Consulting SAS | $73.35 · — to 2033-03-02 | 9,535 Common Stock | (F2) The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. (F3) The option vests in three equal annual installments beginning on March 2, 2024. |